Omega Therapeutics Competitors and Similar CompaniesClear all
Omega Therapeutics's competitors and similar companies include CRISPR Therapeutics, Constellation Pharmaceuticals, Beam Therapeutics and Alnylam.
 CRISPR Therapeutics CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases. |  Constellation Pharmaceuticals Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops novel therapeutics that address serious unmet medical needs in patients with cancers. |  Beam Therapeutics Beam Therapeutics is a biotechnology company that develops precision genetic medicines making edits to individual base pairs in the genetic code. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | ||
Founding Date | Founding Date 2017 | Founding Date 2013 | Founding Date 2008 | Founding Date 2017 | Founding Date 2002 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Public |
Tags | |||||
Locations | Locations Cambridge, US HQ | Locations Zug, CH HQ Greater London, GB Cambridge, US San Francisco, US | Locations Cambridge, US HQ Boston, US | Locations Boston, US HQ | |
Employees | Employees 60 | Employees 393 | Employees 474% decrease | Employees 11229% increase | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 68.4 m | Valuation ($) 4.2 b | Valuation ($) N/A | Valuation ($) 1.8 b | Valuation ($) 36.5 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $3.1m (FY, 2023) | Revenue (est.) $3.5m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $139.7m (FY, 2025) | Revenue (est.) $3.7b (FY, 2025) |
Net income | Net income ($97.4m) (FY, 2023) | Net income ($581.6m) (FY, 2025) | Net income ($35.4m) (FY, 2017) | Net income ($80m) (FY, 2025) | Net income $313.7m (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 211m | Total funding raised $ 127m | Total funding raised $ 403.6m | Total funding raised $ 222m | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View Company Profiles
CRISPR Therapeutics
HQ
Zug, CH
Employees
393
CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases.
View companyConstellation Pharmaceuticals
HQ
Cambridge, US
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops novel therapeutics that address serious unmet medical needs in patients with cancers.
View companyBeam Therapeutics
HQ
Boston, US
Employees
112↑ 29% increase
Beam Therapeutics is a biotechnology company that develops precision genetic medicines making edits to individual base pairs in the genetic code.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company